NCT01745965View on ClinicalTrials.gov

A Prospective, Randomized Multicenter, Open-label Comparison of Preoperative Trastuzumab Emtansine (T-DM1) With or Without Standard Endocrine Therapy vs. Trastuzumab With Standard Endocrine Therapy Given for Twelve Weeks in Patients With Operable HER2+/HR+ Breast Cancer Within the ADAPT Protocol.

PHASE2CompletedINTERVENTIONAL

Enrollment

380

Participants

Timeline

Start Date

November 30, 2012

Primary Completion Date

February 28, 2015

Study Completion Date

January 15, 2025

Conditions

Breast Cancer

Interventions

DRUG

T-DM1

DRUG

Trastuzumab

Trial Locations (2)

Unknown

Ev. Krankenhaus Bethesda Brustzentrum Niederrhien, Mönchengladbach

Breast Center of the University of Munich (LMU), Munich

All Listed Sponsors

collaborator

Roche Pharma AG

INDUSTRY

lead

West German Study Group

OTHER

NCT01745965 - A Prospective, Randomized Multicenter, Open-label Comparison of Preoperative Trastuzumab Emtansine (T-DM1) With or Without Standard Endocrine Therapy vs. Trastuzumab With Standard Endocrine Therapy Given for Twelve Weeks in Patients With Operable HER2+/HR+ Breast Cancer Within the ADAPT Protocol. | Biotech Hunter | Biotech Hunter